What question did this study set out to answer?

The central aim is to assess the dosimetry and biodistribution of 86Y-NM600 using Cherenkov luminescence imaging.

February 9, 2026Open Access

Quantitative in vivo Cherenkov luminescence imaging and dosimetry of 86Y-NM600

CHCampbell HaaschUniversity of Wisconsin–Madison MIMalick Bio IdrissouUniversity of Wisconsin–Madison SJSydney JupitzUniversity of Wisconsin–Madison

Key Points

The central aim is to assess the dosimetry and biodistribution of 86Y-NM600 using Cherenkov luminescence imaging.
Utilized depth-dependent optical attenuation calibration.
Applied Monte Carlo techniques for ionizing scatter correction.
Performed quantitative biodistribution analysis using Cherenkov luminescence imaging.
Demonstrated comparable dosimetry estimates to PET imaging.
Showed high-throughput and low-cost advantages for in vivo dosimetry.
Enabled feasibility of large-scale preclinical radiopharmaceutical studies.

Abstract

With appropriate depth-dependent optical attenuation calibration and Monte Carlo-derived ionizing scatter correction, CLI can provide quantitative biodistribution and dosimetry estimates comparable to PET. This approach enables high-throughput, low-cost in vivo dosimetry, expanding the feasibility of large-scale preclinical RPT studies and supporting translational radiopharmaceutical development.

KI fragen

Bookmark

View Full Paper